This is an open-label, two-part Phase 2 study investigating CGT9486 for the treatment of patients with Advanced Systemic Mastocytosis (AdvSM), including patients with Aggressive SM (ASM), SM with Associated Hematologic Neoplasm (SM-AHN), and Mast Cell Leukemia (MCL).
Advanced Systemic Mastocytosis (AdvSM), SM with an Associated Hematologic Neoplasm (SM-AHN), Mast Cell Leukemia (MCL), Aggressive Systemic Mastocytosis (ASM)
This is an open-label, two-part Phase 2 study investigating CGT9486 for the treatment of patients with Advanced Systemic Mastocytosis (AdvSM), including patients with Aggressive SM (ASM), SM with Associated Hematologic Neoplasm (SM-AHN), and Mast Cell Leukemia (MCL).
(Apex) Bezuclastinib in Patients with Advanced Systemic Mastocytosis
-
University of Alabama at Birmingham (UAB) Hospital, Birmingham, Alabama, United States, 35233
Mayo Clinic Arizona, Phoenix, Arizona, United States, 85054
City of Hope Comprehensive Cancer Center, Duarte, California, United States, 91010
UCLA Medical Center, Los Angeles, California, United States, 90095
Stanford Cancer Institute, Stanford, California, United States, 94305
Galiz Research, Hialeah, Florida, United States, 33016
Winship Cancer Institute - Emory University, Atlanta, Georgia, United States, 30322
Rush University Medical Center, Chicago, Illinois, United States, 60612
Dana-Farber Cancer Institute, Boston, Massachusetts, United States, 02215
Columbia University Irving Medical Center, New York, New York, United States, 10032
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
Cogent Biosciences, Inc.,
Rachael Easton, MD, Ph.D., STUDY_DIRECTOR, Cogent Biosciences, Inc.
2026-07